Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05663957 · ClinicalTrials.gov registry record
eVusheld Assessment reaL wORld Effectiveness in the VA Health System
A clinical trial of SARS-CoV-2, COVID-19, sponsored by AstraZeneca.
- Completed
- Registry status
- 5,814
- Enrollment target
- 1
- Study location
NCT05663957: Completed study of SARS-CoV-2, COVID-19, sponsored by AstraZeneca.
NCT05663957 is a study of SARS-CoV-2, COVID-19 that has completed, run by AstraZeneca. The registered enrollment target is 5,814 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05663957, a study of SARS-CoV-2, COVID-19, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 5,814 participants
- Enrollment target
- 1
- Study location
Study Summary
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient population in the Department of Veterans Affairs (VA) Health System.
Primary Outcome
Hospital record of patient admission
Conditions Studied
Interventions
- DRUG Evusheld
Study Locations (1)
Utah
- Research Site - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,814 participants |
| Start Date | 2023-01-04 |
| Est. Completion | 2023-09-01 |
What the finished NCT05663957 record still lists
NCT05663957 is an observational study that tracks outcomes without assigning an intervention. Its 5,814 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with SARS-CoV-2, COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Evusheld is the first listed.
NCT05663957 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT05663957 about?
NCT05663957 is a clinical study titled "eVusheld Assessment reaL wORld Effectiveness in the VA Health System". An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient popu...
What is the current status of trial NCT05663957?
This trial is currently completed. The enrollment target is 5,814 participants. The study started on 2023-01-04. Estimated completion is 2023-09-01.
What conditions does trial NCT05663957 study?
This clinical trial studies the following conditions: SARS-CoV-2, COVID-19.
What interventions are being tested in trial NCT05663957?
The interventions under investigation include: Evusheld (DRUG).
Who is sponsoring clinical trial NCT05663957?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05663957 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04983875 · 5,708 participants · NA
Mammography and Breast Arterial Calcification: An Information-Sharing Trial
- NCT03959085 · 5,951 participants · Phase 3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- NCT06192511 · 5,980 participants · NA
Implementing a Novel Consent Process for Biospecimen Research After Newborn Screening
- NCT00005095 · 6,000 participants
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI